Codiak BioSciences Stock

codiakbio.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $168.37MM

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need.

Register for Details

For more details on financing and valuation for Codiak BioSciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Codiak BioSciences.

Register Today

Team

Management Team

Douglas E. Williams, Ph.D.
President, Chief Executive Officer & Board Member
Linda C. Bain
Chief Financial Officer
Richard Brudnick
Chief Business Officer & Head of Strategy
Andrea Difabio
Chief Legal Officer

Board Members

Theo Melas-Kyriazi
Jonathan Poole
Eric S. Lander, Ph.D.
Karen Bernstein, Ph.D.
Steven Gillis, Ph.D.
Charles L. Cooney, Ph.D.
Briggs W. Morrison, M.D.
Douglas E. Williams, Ph.D.

Other companies like Codiak BioSciences in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Jazz, Codiak to Partner on Exosome Therapeutics for Cancer in $1B+ Collaboration
Jazz Pharmaceuticals will use Codiak BioSciences’ engEx™ precision engineering platform to research, develop and commercialize exosome therapeutics for cancer through a collaboration that could generate more than $1 billion for Codiak,
Updated on: Sep 25, 2023